Agenus Inc. Common Stock AGEN
i
Market dataready · fetched 2026-11-13T19:10:37.870Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T19:07:04.134369356Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T19:03:00.507185+00:00
Agenus Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.72 | 98.7% | 16.4% | 5.09 | 296.3% | 29.6% |
| 25Δ | 7.55 | 98.6% | 14.4% | 5.33 | 270.7% | 26.3% |
| 30Δ | 7.38 | 98.4% | 12.4% | 5.57 | 245.1% | 23.0% |
| 35Δ | 7.21 | 98.3% | 10.3% | 5.80 | 219.5% | 19.7% |
| 40Δ | 7.03 | 98.1% | 8.3% | 6.04 | 193.8% | 16.4% |
| 45Δ | 6.89 | 101.4% | 7.3% | 6.28 | 168.2% | 13.2% |
| 50Δ | 6.75 | 105.5% | 6.6% | 6.52 | 142.6% | 9.9% |
| 55Δ | 6.61 | 109.7% | 5.9% | 6.76 | 117.0% | 6.6% |
| 60Δ | 6.47 | 113.8% | 5.1% | 7.00 | 91.4% | 3.3% |
| 65Δ | 6.33 | 117.9% | 4.4% | |||
| 70Δ | 6.19 | 122.1% | 3.7% | |||
| 75Δ | 6.05 | 126.2% | 2.9% | |||
| 80Δ | 5.69 | 141.6% | 2.3% | |||
20Δ
- Pseudo strike
- 7.72
- IV
- 98.7%
- B/E move
- 16.4%
- Pseudo strike
- 5.09
- IV
- 296.3%
- B/E move
- 29.6%
25Δ
- Pseudo strike
- 7.55
- IV
- 98.6%
- B/E move
- 14.4%
- Pseudo strike
- 5.33
- IV
- 270.7%
- B/E move
- 26.3%
30Δ
- Pseudo strike
- 7.38
- IV
- 98.4%
- B/E move
- 12.4%
- Pseudo strike
- 5.57
- IV
- 245.1%
- B/E move
- 23.0%
35Δ
- Pseudo strike
- 7.21
- IV
- 98.3%
- B/E move
- 10.3%
- Pseudo strike
- 5.80
- IV
- 219.5%
- B/E move
- 19.7%
40Δ
- Pseudo strike
- 7.03
- IV
- 98.1%
- B/E move
- 8.3%
- Pseudo strike
- 6.04
- IV
- 193.8%
- B/E move
- 16.4%
45Δ
- Pseudo strike
- 6.89
- IV
- 101.4%
- B/E move
- 7.3%
- Pseudo strike
- 6.28
- IV
- 168.2%
- B/E move
- 13.2%
50Δ
- Pseudo strike
- 6.75
- IV
- 105.5%
- B/E move
- 6.6%
- Pseudo strike
- 6.52
- IV
- 142.6%
- B/E move
- 9.9%
55Δ
- Pseudo strike
- 6.61
- IV
- 109.7%
- B/E move
- 5.9%
- Pseudo strike
- 6.76
- IV
- 117.0%
- B/E move
- 6.6%
60Δ
- Pseudo strike
- 6.47
- IV
- 113.8%
- B/E move
- 5.1%
- Pseudo strike
- 7.00
- IV
- 91.4%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 6.33
- IV
- 117.9%
- B/E move
- 4.4%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 6.19
- IV
- 122.1%
- B/E move
- 3.7%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 6.05
- IV
- 126.2%
- B/E move
- 2.9%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.69
- IV
- 141.6%
- B/E move
- 2.3%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 182.95% | |
| 166.24% | |
| 150.79% | |
| 126.56% | |
| 105.63% | |
| 106.18% | |
| 104.86% | |
| 105.07% | |
| 113.14% | |
| 104.20% | |
| 115.29% | |
| 106.76% | |
| 100.51% | |
| 97.08% | |
| 114.46% | |
| 126.71% | |
| 116.05% | |
| 123.96% | |
| 129.63% | |
| 134.83% | |
| 148.50% | |
| 163.51% | |
| 99.94% | |
| 115.18% | |
| 97.57% | |
| 95.16% | |
| 110.71% | |
| 102.83% | |
| 104.03% | |
| 93.62% | |
| 100.01% | |
| 92.54% | |
| 97.19% | |
| 91.44% | |
| 103.25% | |
| 97.47% | |
| 99.84% | |
| 97.63% | |
| 106.88% | |
| 99.31% | |
| 138.60% | |
| 97.36% | |
| 95.88% | |
| 99.87% | |
| 99.50% | |
| 94.49% | |
| 102.61% | |
| 105.88% | |
| 105.08% | |
| 114.86% |
Biotechnology
AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The…
More →AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device…
More →AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve…
More →ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington,…
More →ALEC
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco,…
More →ALLO
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The…
More →